
MC
USDMoelis & Company Class A Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$63.850
Haut
$64.700
Bas
$62.790
Volume
0.95M
Fondamentaux de l'Entreprise
Capitalisation Boursière
4.7B
Industrie
Capital Markets
Pays
United States
Statistiques de Trading
Volume Moyen
0.74M
Bourse
NYQ
Devise
USD
Intervalle sur 52 Semaines
Rapport d'Analyse IA
Dernière mise à jour: 30 oct. 2025MC (Moelis & Company) Analysis: Navigating Volatility in Financial Services Stock
Current Observation (as of Oct 29, 2025): Moelis shares closed at $66.84 after a sharp 6.3% single-day drop following earnings release. The stock remains 19% below its 52-week high ($82.89) but has rebounded 5.8% from recent lows ($63.09 on Oct 10).
Recent Performance Breakdown
- 3-Month Range: $62.88 - $78.05
- Earnings Reaction: 6.3% decline post-Q3 results
- Volume Spike: 180% above average on Oct 29
- Pattern Alert: Testing support near $66 level that held in mid-October
Notable Price Movements:
- 17% August rally followed by 12% September correction
- 14% October decline before partial recovery
- Current price sits between 50-day ($69.12) and 200-day ($70.45) averages
News & Analyst Insights
- Dividend Stability: Maintained $0.65 quarterly dividend
- Mixed Analyst Views:
- Deutsche Bank initiated coverage at Buy ($80 target) on Oct 9
- KBW maintained Outperform but cut target to $80 from $89 on Oct 13
- Financial Highlights:
- Q3 adjusted revenues up 34% YoY
- YTD revenues exceed $1 billion
Technical & Fundamental Check
| Metric | Current Status | Implication |
|---|---|---|
| P/E Ratio | 28.4x | Premium to sector average |
| Debt/Equity | 36.7% | Higher than ideal (threshold: 30%) |
| Volume Surge | 11.8x average | Strong directional conviction |
| MACD | Negative crossover | Short-term bearish signal |
| ROE | 44.8% | Exceptional profitability |
Strategic Considerations
Potential Entry Zones:
- Conservative: $66.50-$67.50 (recent support)
- Confirmation: Break above $69.50 (50-day MA)
Exit Planning:
- Stop Loss: $64.20 (7% below current)
- Take Profit: $72.76 (8.9% upside)
Risk Factors:
- High debt load in rising rate environment
- Market-sensitive revenue streams
- Recent technical breakdown below key MAs
Actionable Outlook
- Short-term (1-2 weeks): Expect continued volatility near earnings gap - range-bound between $64-$69 likely
- Medium-term (3-6 months): $75-80 achievable if financial advisory demand holds
- Investor Fit: Suitable for growth-oriented investors comfortable with sector volatility
Current Positioning Strategy: "Wait for stabilization post-earnings reaction. Consider starter position below $67 with tight stop, adding on confirmed reversal above $69.50."
Disclaimer: This analysis reflects market conditions as of October 30, 2025. Not financial advice. Conduct your own due diligence and consider risk tolerance before investing. Past performance doesn't guarantee future results. Investment values may fluctuate.
Actualités Connexes
Keefe, Bruyette & Woods Maintains Outperform on Moelis, Lowers Price Target to $78
Keefe, Bruyette & Woods analyst Aidan Hall maintains Moelis with a Outperform and lowers the price target from $80 to $78.
Moelis & Company Reports Third Quarter and First Nine Months 2025 Financial Results; Declares Regular Quarterly Dividend of $0.65 Per Share
Third quarter GAAP revenues of $356.9 million; Adjusted revenues of $376.0 million, up 34% from the prior year period GAAP revenues for the first nine months of 2025 were $1,028.9 million; Adjusted revenues of
Keefe, Bruyette & Woods Maintains Outperform on Moelis, Lowers Price Target to $80
Keefe, Bruyette & Woods analyst Aidan Hall maintains Moelis with a Outperform and lowers the price target from $89 to $80.
Prédiction IABeta
Recommandation IA
Mis à jour le: 10 nov. 2025, 19:21
60.7% Confiance
Risque et Trading
Point d'Entrée
$63.31
Prise de Bénéfices
$65.17
Stop Loss
$57.50
Facteurs Clés
Actions Connexes
CVCO
Cavco Industries Inc. When Issued
ATHA
Athira Pharma Inc.
LANDO
Gladstone Land Corporation 6.00% Series B Cumulative Redeemable Preferred Stock
ALFUW
Centurion Acquisition Corp. Warrant
OCX
Oncocyte Corporation
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.